Get the Stockscreener App
4.2413
2.85%
-0.1387
Neuphoria Therapeutics Inc stock is traded at $4.2413, with a volume of 87,245.
It is down -2.85% in the last 24 hours and down -78.13% over the past month.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
See More
Previous Close:
$4.38
Open:
$4.25
24h Volume:
87,245
Relative Volume:
0.06
Market Cap:
$7.99M
Revenue:
$15.66M
Net Income/Loss:
$5.83M
P/E Ratio:
-0.1775
EPS:
-23.8939
Net Cash Flow:
$466.20K
1W Performance:
-9.66%
1M Performance:
-78.13%
6M Performance:
-15.83%
1Y Performance:
+0.00%
1-Day Range:
$4.15
$4.41
1-Week Range:
$4.15
$4.91
52-Week Range:
$2.90
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
4.25 | 10.33M | 15.66M | 5.83M | 466.20K | -23.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.42 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.32 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
426.61 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.02 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.88 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
Is Neuphoria Therapeutics Inc. stock attractive after correctionRate Cut & Fast Exit and Entry Trade Guides - newser.com
Can Neuphoria Therapeutics Inc. stock maintain operating marginsJuly 2025 EndofMonth & Safe Capital Growth Tips - newser.com
Will Neuphoria Therapeutics Inc. stock attract more institutional investorsEarnings Trend Report & Stepwise Trade Execution Plans - newser.com
What indicators show strength in Neuphoria Therapeutics Inc.2025 AllTime Highs & Consistent Return Strategy Ideas - newser.com
Can Neuphoria Therapeutics Inc. stock hit analyst price targets2025 Volatility Report & AI Driven Stock Movement Reports - newser.com
What valuation multiples suggest for Neuphoria Therapeutics Inc. stockJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
How to read the order book for Neuphoria Therapeutics Inc.July 2025 Gainers & Weekly High Conviction Trade Ideas - newser.com
What does recent volatility data suggest for Neuphoria Therapeutics Inc.2025 Investor Takeaways & AI Driven Price Forecasts - newser.com
What Wall Street predicts for Neuphoria Therapeutics Inc. stock priceJuly 2025 Decliners & Breakout Confirmation Alerts - newser.com
Why hedge funds are buying Neuphoria Therapeutics Inc. stockQuarterly Trade Review & Risk Controlled Daily Plans - newser.com
Will Neuphoria Therapeutics Inc. stock deliver shareholder valueTrade Entry Report & Fast Entry High Yield Stock Tips - newser.com
Can Neuphoria Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Weekly Recap & Community Supported Trade Ideas - newser.com
How Neuphoria Therapeutics Inc. stock performs in interest rate cyclesJuly 2025 Earnings & Fast Moving Stock Watchlists - newser.com
Will Neuphoria Therapeutics Inc. stock keep outperforming rivalsEntry Point & Free AI Powered Buy and Sell Recommendations - newser.com
Neuphoria Therapeutics Inc.’s volatility index tracking explainedWeekly Profit Analysis & Low Risk Profit Maximizing Plans - newser.com
Can Neuphoria Therapeutics Inc. stock sustain institutional interestStop Loss & Verified Short-Term Trading Plans - newser.com
Why analysts upgrade Neuphoria Therapeutics Inc. stockShare Buyback & Stock Portfolio Risk Management - newser.com
Using AI based signals to follow Neuphoria Therapeutics Inc.July 2025 Decliners & Low Risk High Reward Ideas - newser.com
Is Neuphoria Therapeutics Inc. showing signs of accumulationQuarterly Earnings Report & Expert Approved Momentum Trade Ideas - newser.com
Neuphoria Therapeutics Inc. (NEUP) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
What drives Neuphoria Therapeutics Inc stock priceEvening Star Patterns & Big Gains Small Budget - earlytimes.in
Why Did NEUP Stock Surge 64% Today? - MSN
Is Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Worth US$4.4 Based On Its Intrinsic Value? - Yahoo Finance
Automated trading signals detected on Neuphoria Therapeutics Inc.Earnings Recap Report & Daily Market Momentum Tracking - newser.com
Best Biotech Stocks To ResearchOctober 26th - MarketBeat
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):